Pierce Protease and Phosphatase Inhibitor Mini Tablets,EDTA-free
Pierce Protease and Phosphatase Inhibitor Mini Tablets,EDTA-free
Thermo Scientific™

Pierce Protease and Phosphatase Inhibitor Mini Tablets,EDTA-free

Thermo Scientific Pierce Protease and Phosphatase Inhibitor Mini Tablets, EDTA-free, contain both protease inhibitors and phosphatase inhibitors to provide broad-spectrum자세히 알아보기
Have Questions?
카탈로그 번호수량
A3296120 Tablets
카탈로그 번호 A32961
제품 가격(KRW)
402,000
온라인 행사
Ends: 31-Dec-2025
446,000
할인액 44,000 (10%)
Each
카트에 추가하기
수량:
20 Tablets
제품 가격(KRW)
402,000
온라인 행사
Ends: 31-Dec-2025
446,000
할인액 44,000 (10%)
Each
카트에 추가하기
Thermo Scientific Pierce Protease and Phosphatase Inhibitor Mini Tablets, EDTA-free, contain both protease inhibitors and phosphatase inhibitors to provide broad-spectrum complete protection from dephosphorylation and proteolytic degradation.

Features of Protease and Phosphatase Inhibitor Mini Tablets, EDTA-free:
Improved formulation—tablets dissolve quickly to form a clear solution
Economical—more cost effective than other commercially available formulations for equivalent volumes
Convenient—ready-to-use, fully disclosed, broad-spectrum formulations
Compatible—use directly with Pierce BCA assays
EDTA-free—formulated without EDTA, a metalloproteinase inhibitor (only for EDTA-free formulations)

The Pierce Protease and Phosphatase Inhibitor Mini Tablets contain aprotinin, bestatin, E-64, and leupeptin to provide protection from degradation by serine proteases, cysteine proteases, and aspartic acid proteases. To prevent the dephosphorylation activity of serine/threonine and tyrosine phosphatases, each tablet also contains sodium fluoride, sodium orthovanadate, sodium pyrophosphate, and beta-glycerophosphate. Pierce Protease and Phosphatase Inhibitor Tablets are stable at 4°C for up to 12 months, and each tablet is sufficient for 10 mL of solution.

Pierce Protease and Phosphatase Inhibitor Mini Tablets are the first complete inhibitor tablet. Adding one tablet to 10 mL of lysis buffer provides complete protection from protease and phosphatase activity during protein extraction and protein purification. There are two formulations of this inhibitor available, one containing EDTA and one without. While both formulations have metalloprotease inhibitors, an EDTA-free formulation is available for applications that require divalent cations for protein activity. Similarly, EDTA and certain phosphatase inhibitors interfere with immobilized metal chelate affinity chromatography (IMAC) and 2D electrophoresis. Dialyze or desalt the sample before performing these procedures. The Protease and Phosphatase Inhibitor formulation is mass spectrometry-compatible because it does not contain AEBSF.

Related products
Pierce Phosphatase Inhibitor Mini Tablets
Pierce Protease Inhibitor Mini Tablets, EDTA-free

For Research Use Only. Not for use in diagnostic procedures.
사양
억제제Protease Inhibitor, Phosphatase Inhibitor
수량20 Tablets
배송 조건Wet Ice
충분10 mL Solution
형태Solid
제품라인Pierce
제품 유형Protease and Phosphatase Inhibitor
Unit SizeEach
구성 및 보관
1 Vial, Store at 2°C to 8°C

자주 묻는 질문(FAQ)

Can I use just part of the Pierce Protease Inhibitor XL Capsules, EDTA-Free and save part of the capsule for later use?

We do not recommend “splitting” the capsule into smaller portions. Researchers using less than 500 mL should choose a different format (liquid or tablet) of protease inhibitors.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

What formats of protease inhibitors do you offer?

We offer standalone protease inhibitors (AEBSF, Aprotinin, PMSF, EDTA, etc.), as well as cocktails or combinations of protease inhibitors in liquid, tablet, and larger capsule formats. These cocktails of protease inhibitors can also be purchased in combination with a cocktail of phosphatase inhibitors, in both liquid and tablet form, for even greater convenience.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

Do you offer any of the components of the Pierce protease, phosphatase and (protease and phosphatase) inhibitor tablets and mini tablets individually?

Yes, the following components of the Pierce protease, phosphatase and (protease and phosphatase) inhibitor tablets and mini tablets are offered separately:

- AEBSF (Cat. No. 78431)
- Aprotinin (Cat. No. 78432)
- Bestatin (Cat. No. 8433)
- E-64 (Cat. No. 78434)
- Leupeptin (Cat. No. 78435)
- Pepstatin A (Cat. No. 78436)
- EDTA (Cat. No. 17892).

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

What are the concentrations of the various components of the protease and phosphatase inhibitor tablets and mini tablets?

The final concentration of each component in the protease and phosphatase inhibitor tablets and mini tablets is proprietary. We release only the identities of the inhibitors.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

Can I store the reconstituted solution of protease, phosphatase and (protease and phosphatase) inhibitor tablet or mini tablet and if so, for how long?

The Pierce protease, phosphatase, as well as (protease and phosphatase) inhibitor tablets and mini tablets are stable for at least one year when stored at 4 degrees C, but we only recommend preparing fresh solutions just before needed. If you are interested in liquid protease or phosphatase inhibitors, please use our inhibitor cocktails (https://www.thermofisher.com/search/results?query=protease%20inhibitor%20cocktails&focusarea=Search%20All).

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

인용 및 참조 문헌 (4)

인용 및 참조 문헌
Abstract
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.
Authors:Robles-Oteíza C,Hastings K,Choi J,Sirois I,Ravi A,Expósito F,de Miguel F,Knight JR,López-Giráldez F,Choi H,Socci ND,Merghoub T,Awad M,Getz G,Gainor J,Hellmann MD,Caron É,Kaech SM,Politi K
Journal:The Journal of experimental medicine
PubMed ID:39585348
Despite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors respond eventually develop acquired resistance (AR). To identify novel drivers of AR, we generated murine Msh2 knock-out (KO) lung tumors ... More
Bioorthogonal Conjugation-Assisted Purification Method for Profiling Cell Surface Proteome.
Authors:Liu G,Choi MH,Ma H,Guo X,Lo PC,Kim J,Zhang L
Journal:Analytical chemistry
PubMed ID:35019258
Surface biotinylation has been widely adapted in profiling the cellular proteome associated with the plasma membrane. However, the workflow is subject to interference from the cytoplasmic biotin-associated proteins that compete for streptavidin-binding during purification. Here we established a bioorthogonal conjugation-assisted purification (BCAP) workflow that utilizes the Staudinger chemoselective ligation to ... More
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Authors:Robles-Oteíza C, Hastings K, Choi J, Sirois I, Ravi A, Expósito F, de Miguel F, Knight JR, López-Giráldez F, Choi H, Socci ND, Merghoub T, Awad M, Getz G, Gainor J, Hellmann MD, Caron É, Kaech SM, Politi K.
Journal:J Exp Med
PubMed ID:39585348
Despite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors respond eventually develop acquired resistance (AR). To identify novel drivers of AR, we generated murine Msh2 knock-out (KO) lung tumors ... More
Mitochondria dysregulation contributes to secondary neurodegeneration progression post-contusion injury in human 3D in vitro triculture brain tissue model.
Authors:Liaudanskaya V,Fiore NJ,Zhang Y,Milton Y,Kelly MF,Coe M,Barreiro A,Rose VK,Shapiro MR,Mullis AS,Shevzov-Zebrun A,Blurton-Jones M,Whalen MJ,Symes AJ,Georgakoudi I,Nieland TJF,Kaplan DL
Journal:Cell death & disease
PubMed ID:37537168
Traumatic Brain injury-induced disturbances in mitochondrial fission-and-fusion dynamics have been linked to the onset and propagation of neuroinflammation and neurodegeneration. However, cell-type-specific contributions and crosstalk between neurons, microglia, and astrocytes in mitochondria-driven neurodegeneration after brain injury remain undefined. We developed a human three-dimensional in vitro triculture tissue model of a ... More